Clinical

The investigators of this new study wanted to more clearly define the patient characteristics of the 2 main types of chronic rhinosinusitis: with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP).

The study probed the role of body weight on gut permeability and systemic inflammation and the impact on asthma control and asthma status.

High levels of interleukin (IL)-26 levels correlate with an exaggerated inflammatory response that signifies severe cases of the disease, according to researchers.

The authors of the retrospective, observational study said it was the first to use electronic medical records to make direct comparisons of these 4 biologics for asthma.

A research letter published in Blood Advances details the first clinical evidence of sustained hematologic remission for cold agglutinin disease (CAD) after sutimlimab treatment discontinuation.

The biologic is the first drug that aims to delay the diagnosis of type 1 diabetes.

As providers strive to deliver seamless, collaborative, and deeply engaging care, advances focused on treating the whole health of a person, wherever they are in their care journey, will be necessary as the health care system continues to evolve to meet the needs of patients and providers alike.

New data show patients treated with chimeric antigen receptor (CAR) T-cell therapy as salvage therapy tended to have meaningful results despite treatment failure following B-cell maturation antigen (BCMA) CAR T.

Experts from US Oncology, Tennessee Oncology, AON, and COA dig into the details of implementing the Enhancing Oncology Model, set to take effect July 1, 2023.

Medical experts illustrate characteristics in the presentation of lupus nephritis.

Alvin Wells, MD, PhD, opens a discussion surrounding systemic lupus erythematosus (SLE) and lupus nephritis (LN).

The 10-year follow-up in the DIACAM 1 study demonstrated a notable increase in prevalence of different types of autoimmune diseases among patients with type 1 diabetes (T1D).

The State of Lung Cancer 2022 report issued by the American Lung Association illustrates aspects of diagnosis and care that require additional attention to address disparities and increase nationwide screening and treatment engagement while reducing risk factor exposure.

A new study has found that a low dose of antidepressants and issues with adherence may contribute to ongoing anxiety or depression among patients with epilepsy on drug therapy.

Switching from the originator products to biosimilars or between biosimilars is safe and effective, according to a review of real-world studies.

A systematic review and meta-analysis presented at ACR Convergence 2022 provide insight into the effects of belimumab in patient populations with cutaneous lupus erythematosus, with or without systemic lupus erythematosus (SLE).

Authors also found that the mortality rate of people with cutaneous lupus erythematosus (CLE) are generally similar to that of the general population.

This international study, from investigators in Germany and Austria, looked at the effect sacubitril/valsartan can have among patients who have heart failure with reduced ejection fraction (HFrEF) and the impact on their cardiac autonomic nervous system.

In addition to the drug approval, the FDA approved a companion diagnostic to be used to identify patients who are eligible to receive the treatment.

Key opinion leaders provide their final thoughts on treatment management for patients with MDS.

The child living with spinal muscular atrophy (SMA) type 2 had less fatigue and improved functional scores as time went on.

These second-generation basal insulin analogs, Gla-300 and IDeg-100, also had similar safety profiles, investigators found.

Despite knowledge of chronic rhinosinusitis and inflammatory bowel diseases (IBDs) sharing dysfunctional mucosa, little is known of potential associations between sinusitis and IBD, which prompted this new study.

This new study shows how using electronic health record (EHR) data can objectively quantify patient treatment burden among individuals who have multiple myeloma (MM) compared with patient-reported outcomes, which can be subject to recall bias.

Laura Bobolts, PharmD, BCOP, discusses key cost drivers impacting treatments for upper GI and esophageal cancers.